Second-line therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a systematic review and mixed-treatment comparison meta-analysis.
about
The treatment of type 2 diabetes in the presence of renal impairment: what we should know about newer therapiesWhat's next after metformin? focus on sulphonylurea: add-on or combination therapyEffects of glucagon-like peptide-1 receptor agonists on weight loss in patients with type 2 diabetes: a systematic review and network meta-analysisUpdate on the treatment of type 2 diabetes mellitusSystematic review and mixed treatment comparison meta-analysis of randomized clinical trials of primary oral antifungal prophylaxis in allogeneic hematopoietic cell transplant recipientsComparative efficacy and safety of antidiabetic drug regimens added to metformin monotherapy in patients with type 2 diabetes: a network meta-analysisCost-Effectiveness of Saxagliptin versus Acarbose as Second-Line Therapy in Type 2 Diabetes in ChinaImplementation and Evaluation of a Wiki Involving Multiple Stakeholders Including Patients in the Promotion of Best Practices in Trauma Care: The WikiTrauma Interrupted Time Series ProtocolClosing Open MedicineWikis and collaborative writing applications in health care: a scoping reviewWikis and collaborative writing applications in health care: a scoping review protocolTen-Year Trends in the Morbidity of Diabetes Mellitus and Antidiabetic Drug Utilization in Croatia: A Study Based on Routinely Collected Data.Combined use of basal insulin analog and acarbose reduces postprandial glucose in patients with uncontrolled type 2 diabetes.Real-life effectiveness and tolerability of vildagliptin and other oral glucose-lowering therapies in patients with type 2 diabetes in Germany.Indirect comparison of lixisenatide versus neutral protamine Hagedorn insulin as add-on to metformin and sulphonylurea in patients with type 2 diabetes mellitus.Clinical outcomes and health care costs combining metformin with sitagliptin or sulphonylureas or thiazolidinediones in uncontrolled type 2 diabetes patientsEffectiveness and Tolerability of Second-Line Therapy with Vildagliptin Versus Other Oral Agents in Type 2 Diabetes (EDGE): Post Hoc Sub-Analysis of Bulgarian Data.Cost-utility analysis of glucagon-like Peptide-1 agonists compared with dipeptidyl peptidase-4 inhibitors or neutral protamine hagedorn Basal insulin as add-on to metformin in type 2 diabetes in swedenObservational and clinical trial findings on the comparative effectiveness of diabetes drugs showed agreement.Efficacy and safety of canagliflozin alone or as add-on to other oral antihyperglycemic drugs in Japanese patients with type 2 diabetes: A 52-week open-label study.Cost-effectiveness of second-line antihyperglycemic therapy in patients with type 2 diabetes mellitus inadequately controlled on metforminHealth care costs in people with diabetes and their association with glycemic control and kidney function.Efficacy and safety of combination therapy with vildagliptin and metformin versus metformin up-titration in Chinese patients with type 2 diabetes mellitus: study design and rationale of the vision studyClinical practice guideline for the prevention, early detection, diagnosis, management and follow up of type 2 diabetes mellitus in adults.Effectiveness and safety of glimepiride and iDPP4, associated with metformin in second line pharmacotherapy of type 2 diabetes mellitus: systematic review and meta-analysis.Comparison of acarbose and voglibose in diabetes patients who are inadequately controlled with basal insulin treatment: randomized, parallel, open-label, active-controlled study.Perspectives and experiences of health care professionals and patients regarding treatments for type 2 diabetes.Liraglutide Versus SGLT-2 Inhibitors in People with Type 2 Diabetes: A Network Meta-AnalysisUntapped diamonds for untamed diabetes: The α-glucosidase inhibitorsPrescription Patterns and the Cost of Antihyperglycemic Drugs in Patients With Type 2 Diabetes Mellitus in Germany.Pharmacogenetics: Implications for Modern Type 2 Diabetes Therapy.Hypoglycaemia when adding sulphonylurea to metformin: a systematic review and network meta-analysis.Effects of Vildagliptin Add-on Insulin Therapy on Nocturnal Glycemic Variations in Uncontrolled Type 2 Diabetes.Systematic review and network meta-analysis comparing palbociclib with chemotherapy agents for the treatment of postmenopausal women with HR-positive and HER2-negative advanced/metastatic breast cancerEffectiveness and safety of fixed dose combination of acarbose/metformin in Indian Type 2 diabetes patients: Results from observational GLOBE Study.Estimating the effects of second-line therapy for type 2 diabetes mellitus: retrospective cohort study.Individualized Glycemic Control for U.S. Adults With Type 2 Diabetes: A Cost-Effectiveness Analysis.DPP-4 Inhibitor-Induced Rheumatoid Arthritis Among Diabetics: A Nested Case-Control Study.
P2860
Q26744317-AB3411F5-3819-4F1B-847F-6326D5E67135Q26786524-F1124E6C-5B05-4BF0-B17B-58997934B71AQ27012696-41D3E11B-DB34-4007-B06E-1BF5CCDD613AQ28073342-2F2715B1-5E64-4070-B8E2-A348F173B5C7Q28083874-F67005A8-06A9-4B0A-9001-CF78FA53AF41Q28546797-EB66BDB9-82F0-4A3F-B75A-148DFB373305Q28553675-15E3C4F0-BFCA-4A89-9C51-0220DF55B6EBQ28651233-E86A09E3-0280-4E14-9762-73ECCC711158Q28651501-E77CD896-6E36-43B8-9219-59B563D00D63Q28658884-AA23E39C-A29B-4EFF-BFBC-3E2368175D26Q28709063-7C0B9525-A48C-409F-B944-AAEFF003048FQ31117837-AFEC3ECD-4476-4E96-8266-7A6D697E5009Q33464541-BCDAB556-D9AA-4907-9FE9-2FCEF62ECF91Q33785162-C43245AA-E8EC-432F-896C-BD2126C3537EQ34368524-9C6D2BEA-FC32-4A95-AF06-FB7D8907DB42Q34415397-7EC5BFE3-25AD-4914-9991-1C03AE8DBF33Q34726395-2EC4F93A-FF3E-4716-8519-F4EBD63B9473Q34726534-4E82CB91-DE24-4869-BE65-8F40ECAE46E2Q35146648-42377110-39E3-4F92-94D6-F1F6AB0EBE84Q35192198-2053335D-6688-4AC5-B3C5-67E0996F773BQ35551069-B06DB8E4-1A86-4022-AFA0-D964442BC10BQ36782623-9BDE2F6C-288D-474D-9BEE-DED52F8A4866Q37153711-4CD81648-545C-4FEB-835C-9AC01A372C58Q37154927-033B5B81-D720-498A-8AAC-B5B6DCCA7819Q37257372-4BFF738F-10D7-480F-8BAF-12942F1A4484Q37473701-8CDF2D7A-36A5-44C5-A0B0-2251D1393483Q37537092-6F846C30-7B9D-4AB1-8904-3307CF80C8BAQ37639297-C7EB2DE5-89B1-4120-B542-545493CBCB8BQ37703682-0C5AAB95-EFAF-4AF1-9A4C-396EA8A95EC5Q37732210-FE0C1AB0-4ED5-48A2-BC8C-6F0DA947F218Q38816602-D5F20217-9A9A-4AD1-A22B-25D284F334A7Q38899869-775D985A-71A3-4581-8FBC-751881E458A4Q42371748-59026D57-3C65-4BF2-B1D1-9410DDFE239EQ42683556-9A4172D9-963E-496F-8FDE-DD340DA45DF1Q43096989-20D7BBD7-A517-4557-9A2F-6E11A2B40B22Q47160310-07CD5559-DC10-403E-B7DF-2195BC740E1AQ47195337-3071CA77-132A-477C-9E03-CC08EE37C814Q47318130-F191B370-7DC2-4869-A1B3-42A58CF66F4C
P2860
Second-line therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a systematic review and mixed-treatment comparison meta-analysis.
description
2011 nî lūn-bûn
@nan
2011 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մարտին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Second-line therapy in patient ...... ment comparison meta-analysis.
@ast
Second-line therapy in patient ...... ment comparison meta-analysis.
@en
type
label
Second-line therapy in patient ...... ment comparison meta-analysis.
@ast
Second-line therapy in patient ...... ment comparison meta-analysis.
@en
prefLabel
Second-line therapy in patient ...... ment comparison meta-analysis.
@ast
Second-line therapy in patient ...... ment comparison meta-analysis.
@en
P2093
P2860
P31
P921
P1433
P1476
Second-line therapy in patient ...... ment comparison meta-analysis.
@en
P2093
Brendan McIntosh
Changhua Yu
Chris Cameron
Marshall Dahl
Nicky J Welton
Sumeet R Singh
Tarun Ahuja
P2860
P304
P577
2011-03-01T00:00:00Z